Newsfeeds - Spark Newswire

1 minute read

Connect Biopharma Announced CBP-201 Atopic Dermatitis China Pivotal Study Met Primary And Secondary Endpoints

March 18, 2:55 PM

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

CNTB

3 minute read

News

Connect Biopharma Provides Business And Clinical Development Program Update

By Benzinga Newsdesk

December 30, 8:31 AM

Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today provided a

CNTB

1 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

October 11, 8:13 AM

Gainers DICE Therapeutics (NASDAQ:DICE) stock moved upwards by 83.4% to $45.2 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.7 billion.

ALBO

2 minute read

Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday

By Lisa Levin

October 5, 5:10 AM

Losers

AMV

1 minute read

Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients

By Vandana Singh

October 4, 11:40 AM

Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results for the primary analysis population of the pivotal trial of CBP-201, in patients…

CNTB

3 minute read

Connect Biopharma Reports CBP-201 Achieved All Primary And Key Secondary Endpoints In Pivotal Atopic Dermatitis (AD) Trial In China

By Bill Haddad

October 4, 7:01 AM

All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe AD Safety and tolerability results for CBP-201 consistent with targeting the

CNTB

1 minute read

Connect Biopharma To Host A Conference Call Tuesday, October 4 To Discuss Topline Results For The Pivotal Trial In China Of Lead Candidate, CBP-201, In Patients With Moderate-To-Severe Atopic Dermatitis

By Benzinga Newsdesk

October 3, 4:21 PM

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT, tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited

CNTB

1 minute read

Earnings

Earnings Scheduled For September 13, 2022

By Benzinga Insights

September 13, 4:52 AM

Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.19 per share on revenue of $42.62 million.

ASPU

4 minute read

Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 30, 6:07 PM

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib)…

AMGN

1 minute read

Connect Biopharma’s Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile

By Vandana Singh

August 30, 9:36 AM

Connect Biopharma Holdings Limited (NASDAQ:CNTB) has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. CBP-174, a highly selective,…

CNTB